期刊文献+

mRNA疫苗的研究进展 被引量:4

Progress in research on mRNA vaccines
原文传递
导出
摘要 近年来随着生物技术的发展,疫苗的研发策略不再仅限于传统的疫苗,曾经被认为有较多局限性的mRNA疫苗在通过一系列研究和改进后,表现出其优越性的一面,已经在肿瘤、感染性疾病及自身免疫性疾病的防控和治疗等方面展示出了良好的应用前景。本文对mRNA疫苗的结构设计和优化及传递系统和疾病防治应用方面取得的进展作一综述。 With the development of biotechnology,the development strategy of vaccines is no longer limited to that of traditional vaccines.The mRNA vaccines,which were once considered to have multiple limitations,have shown their advantages after a series of structural modifications as well as a good application prospect in the prevention,control and treatment of tumors,infectious diseases and autoimmune diseases.This paper reviews the progress in research on structural design and optimization,delivery system and applications in prevention and control of diseases of mRNA vaccines.
作者 袁军鸿 杨昭庆(综述) 马绍辉(审校) YUAN Jun-hong;YANG Zhao-qing;MA Shao-hui(Kunming Medical University,Kunming 650500,Yunnan Province,China)
出处 《中国生物制品学杂志》 CAS CSCD 北大核心 2022年第6期734-739,共6页 Chinese Journal of Biologicals
基金 云南省高层次卫生健康技术人才培养专项(L-2018003) 中国医学科学院医学与健康科技创新工程(2016-I2M-3-026)。
关键词 mRNA疫苗 结构优化 肿瘤治疗 感染性疾病 传递系统 mRNA vaccine Structure optimization Oncotherapy Infectious disease Delivery system
  • 相关文献

参考文献8

二级参考文献70

  • 1Rettig WJ, Old LJ. Immunogenetics of human cell surface differentiation [J]. Annu Rev Immunol, 1989, 7: 481-511.
  • 2Hughes B. Antibody-drug conjugates for cancer: poised to deliver?[J]. Nat Rev Drug Discov, 2010, 9(9): 665-667.
  • 3Dronca RS, Dong H. Immunomodulatory antibody therapy of cancer: the closer, the better[J]. Clin Cancer Res, 2015, 21(5): 944-946.
  • 4Kuroki M, Shirasu N. Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens[J]. Anticancer Research, 2014, 34(8): 4481-4488.
  • 5Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer [J]. Nat Rev Cancer, 2012, 12(4): 278-287.
  • 6Zeng Y, Wu XX, Fiscella M, et al. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo[J]. Int J Oncol, 2006, 28(2): 421-430.
  • 7Ming LC, Stephenson R, Salazar AM, et al. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells[J]. Oncoimmunology, 2013, 2(6): e24677.
  • 8Casi G, Neri D. Antibody-drug conjugates: Basic concepts, examples and future perspectives[J]. J Control Release, 2012, 161(2): 422-428.
  • 9Rech AJ, Mick R, Martin S, et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients[J]. Sci Transl Med, 2012, 4(134): 134ra62.
  • 10Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations[J]. Cancer Med, 2015, 4(5): 661-672.

共引文献39

同被引文献49

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部